Endocrine pancreatic tumors (EPT) are rare tumors that produce glucagon in less than 1% of them (1).
< 37U/mL). An abdominal CT scan showed a nodule of 1.7 cm in the tail of the pancreas. The study was completed with a MRI which confirmed the presence of the nodule and, because of its vascular behaviour, the diagnosis of neuroendocrine tumor was suggested.
Octreotide scintigraphy showed a lesion that expressed somatostatin receptors. Serum levels of various hormones (VIP, glucagon, gastrin, insulin and chromogranin A) were negative except for chromogranin A which was elevated (369 ng/mL; VN: < 133 ng/mL).
The patient underwent corporocaudal espleno-pancreatectomy. After intervention, octreotide scintigraphy was normal. Currently, the patient continues his revisions in consultation of Surgery and he is asymptomatic.
Discussion
Glucagon-secreting EPT are originated in alpha cells from the pancreas, but they may arise from ductal epithelial stem cells (2) . They appear in middle-aged adults. They usually are large pan- creatic tumors that are associated with MEN syndrome type 1 in up to 3-5% of the cases (3). They are characterized by the glucagonoma syndrome: necrolytic migratory erythema, glucose intolerance, anemia, weight loss, diarrhea, abdominal pain, venous thrombosis and neuropsychiatric symptoms.
Although necrolytic migratory erythema is very characteristic, is not pathognomonic. The rash consists of itchy and painful erythematous plaques located anywhere in the body (4) .
Less common are cases of incidental diagnosis, such as our case. Other cases reported in the literature were also atypical, such as a patient who debuted with diabetic ketoacidosis (5) or another one with a malignant primary liver mass (6) .
They can be suspected by hyperglucagonemia (levels > 500 pg/mL), hyperglycemia, hypoproteinemia, and normocytic-normochromic anemia (7) .
In our case only a significant elevation of chromogranin A and an incidental detection of the elevated CA19.9 allowed us an early diagnosis.
The study should be completed with an abdominal CT or a MRI of the pancreas, which can also identify metastases, and should also be confirmed with an octreotide scintigraphy.
The treatment includes the surgical resection in the absence of distant metastases. Otherwise, somatostatin analogs, such as octreotide, should be used to improve symptoms.
In our case, we were able to remove completely the tumor due to its small size.
The prognosis is uncertain. Fifty to eighty percent of patients have metastases in the liver, lymph nodes or bone at diagnosis (8) . However, patients may have prolonged survival.
